Min Dong1, Tsuyoshi Fukuda1,2, Sally Selim3, Mark A Smith3, Laura Rabinovich-Guilatt3, James V Cassella4, Alexander A Vinks5,6. 1. Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 6018, Cincinnati, OH, 45229-3039, USA. 2. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 3. Teva Pharmaceuticals, Frazer, PA, USA. 4. Alexza Pharmaceuticals, Inc., Mountain View, CA, USA. 5. Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 6018, Cincinnati, OH, 45229-3039, USA. sander.vinks@cchmc.org. 6. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. sander.vinks@cchmc.org.
Abstract
BACKGROUND AND OBJECTIVES: Loxapine for inhalation is a drug-device combination product approved in adults for the acute treatment of agitation associated with schizophrenia or bipolar I disorder. The primary objective of this study was to develop a clinical trial protocol to support a phase I pharmacokinetic study in children aged 10 years and older. In addition, this report details the results of the clinical study in relation to the predicted likelihood of achieving the target exposure associated with therapeutic effect in adults. METHODS: A nonlinear mixed-effects population pharmacokinetic model was developed using adult data and was adjusted for the targeted pediatric age groups by applying allometric scaling to account for body size effects. Based on this pediatric model, age-appropriate regimens to achieve loxapine exposures similar to the ones associated with therapeutic effect in the adult studies were identified via trial simulation. D-optimal design and power analysis were conducted to identify optimal pharmacokinetic sampling times and sample size, respectively. RESULTS: The developed clinical trial design formed the basis of a phase I study to assess the safety and pharmacokinetics of loxapine for inhalation in children aged 10 years and older (ClinicalTrials.gov ID: NCT02184767). CONCLUSION: The results of the study indicated that overall loxapine exposures were consistent with what had been predicted by the trial simulations. The presented approach illustrates how modeling and simulation can assist in the design of informative clinical trials to identify safe and effective doses and dose ranges in children and adolescents.
BACKGROUND AND OBJECTIVES:Loxapine for inhalation is a drug-device combination product approved in adults for the acute treatment of agitation associated with schizophrenia or bipolar I disorder. The primary objective of this study was to develop a clinical trial protocol to support a phase I pharmacokinetic study in children aged 10 years and older. In addition, this report details the results of the clinical study in relation to the predicted likelihood of achieving the target exposure associated with therapeutic effect in adults. METHODS: A nonlinear mixed-effects population pharmacokinetic model was developed using adult data and was adjusted for the targeted pediatric age groups by applying allometric scaling to account for body size effects. Based on this pediatric model, age-appropriate regimens to achieve loxapine exposures similar to the ones associated with therapeutic effect in the adult studies were identified via trial simulation. D-optimal design and power analysis were conducted to identify optimal pharmacokinetic sampling times and sample size, respectively. RESULTS: The developed clinical trial design formed the basis of a phase I study to assess the safety and pharmacokinetics of loxapine for inhalation in children aged 10 years and older (ClinicalTrials.gov ID: NCT02184767). CONCLUSION: The results of the study indicated that overall loxapine exposures were consistent with what had been predicted by the trial simulations. The presented approach illustrates how modeling and simulation can assist in the design of informative clinical trials to identify safe and effective doses and dose ranges in children and adolescents.
Authors: Julia Dunne; William J Rodriguez; M Dianne Murphy; B Nhi Beasley; Gilbert J Burckart; Jane D Filie; Linda L Lewis; Hari C Sachs; Philip H Sheridan; Peter Starke; Lynne P Yao Journal: Pediatrics Date: 2011-10-24 Impact factor: 7.124
Authors: Khe Dinh; Dan J Myers; Marc Glazer; Tamara Shmidt; Caitlin Devereaux; Kathleen Simis; Peter D Noymer; Min He; Corinna Choosakul; Qiang Chen; James V Cassella Journal: Int J Pharm Date: 2010-10-31 Impact factor: 5.875
Authors: Jiang Ping Luo; Sarvesh C Vashishtha; Edward M Hawes; Gordon McKay; Kamal K Midha; Jim Fang Journal: Biopharm Drug Dispos Date: 2011-08-09 Impact factor: 1.627
Authors: Jennifer S D Zimmer; Shane R Needham; Chad D Christianson; Crystal M Piekarski; Chrystal N Sheaff; Keith Huie; Andrea R Reed; Lori Takahashi Journal: Bioanalysis Date: 2010-12 Impact factor: 2.681
Authors: Elke H J Krekels; Johan G C van Hasselt; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe Journal: Pharm Res Date: 2010-12-14 Impact factor: 4.200
Authors: Min Dong; Patrick T McGann; Tomoyuki Mizuno; Russell E Ware; Alexander A Vinks Journal: Br J Clin Pharmacol Date: 2016-02-05 Impact factor: 4.335
Authors: Elisa A M Calvier; Elke H J Krekels; Pyry A J Välitalo; Amin Rostami-Hodjegan; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe Journal: Clin Pharmacokinet Date: 2017-03 Impact factor: 6.447
Authors: Kana Mizuno; Christopher E Dandoy; Ashley Teusink-Cross; Stella M Davies; Alexander A Vinks; Sonata Jodele Journal: Blood Adv Date: 2022-03-08